Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945182 | 1.00 | SIGMAR1 (0.47) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| SCHEMBL1880066 | 1.00 | SIGMAR1 (0.47) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1442190 | 0.98 | SIGMAR1 (0.46) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1442192 | 0.98 | SIGMAR1 (0.46) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1730624 | 0.98 | SIGMAR1 (0.46) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| SCHEMBL31048186 | 0.91 | SPHK2 (0.49) | SIGMAR1GBA1SPHK2SPHK1PDK1 | |
| SCHEMBL2465869 | 0.88 | SIGMAR1 (0.54) | SIGMAR1POLB | |
| SCHEMBL2465872 | 0.88 | SIGMAR1 (0.54) | SIGMAR1POLB | |
| SCHEMBL14995124 | 0.86 | — | — | |
| SCHEMBL2459177 | 0.86 | LTA4H (0.42) | SIGMAR1GBA1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| CN-115916790-A | Pyrido [2,3-b ] [1,4] oxazines or tetrahydropyrido [2,3-b ] [1,4] oxazepines as IAP antagonists | 百济神州有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-5175158-A | CONDENSED DIAZEPINONES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | DR. KARL THOMAE, GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0254955-B1 | Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1992-05-27 | — | — | EP | disclosed |
| EP-0306698-B1 | CONDENSED DIAZEPINONES, PROCESSES FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1992-03-25 | — | — | EP | disclosed |
| US-5068234-A | Analgesics, rheumatic diseases, antiinflammatory agents or antiglaucoma | STERLING DRUG INC. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0444451-A2 | 3-Arylcarbonyl-1H-indoles useful as therapeutic agents | STERLING WINTHROP INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-4971966-A | BRADYCARDIAL, CARDIOVASCULAR DISORDERS | KARL THOMAE GMBH (DE) | 1990-11-20 | — | — | US | disclosed |
| US-4931436-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1990-06-05 | — | — | US | disclosed |
| EP-0312895-A2 | Condensed diazepinones, process for their preparation and medicament containing them | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | disclosed |
| EP-0306698-A1 | Condensed diazepinones, processes for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0254955-A2 | Substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146483-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | SIGMAR1 247/4885S1PR1 288/4885GBA1 1113/4885 |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | SIGMAR1 1970/4885S1PR1 2264/4885GBA1 4579/4885 |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ADORA2A, ADORA1, ADORA3 | SIGMAR1 171/4885S1PR1 368/4885GBA1 453/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | SIGMAR1 2815/4885S1PR1 1479/4885GBA1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.